Patient demographics and disease characteristics
| Patient . | Age, y . | Sex . | MM subtype . | R-ISS stage . | Induction regimen . | Dz status pre-ASCT . | Antigen screening . | Dz status +3 mo . | Dz status +12 mo . | ||
|---|---|---|---|---|---|---|---|---|---|---|---|
| CT7 . | MAGE-A3 . | WT1 . | |||||||||
| Control arm | |||||||||||
| 4 | 65 | F | IgGλ | III− t(4;14) | RVd | VGPR | Neg | Neg | +1 | VGPR | Relapse |
| 6 | 66 | F | IgGκ | II | RVd | VGPR | +3 | +2 | +2 | VGPR | VGPR |
| 8 | 51 | M | IgAλ | III | CyBorD | VGPR | Focal | Neg | Neg | CR (+) | Relapse |
| 10 | 61 | F | IgAκ | I | RVd | VGPR | Neg | Neg | +1 | CR (−) | CR (+) |
| 12 | 65 | M | κFLC | II | CyBorD | VGPR | +2 | +1 | Neg | CR (+) | CR (−) |
| 14 | 52 | F | IgAλ | III− t(14;16) | KRd | CR (−) | Focal | Neg | Neg | Relapse | Relapse |
| 16 | 56 | M | IgGκ | I | KRd | VGPR | +2 | Neg | Neg | VGPR | VGPR |
| 17 | 59 | M | IgGκ | II | KRd | VGPR | Focal | Neg | Neg | CR (+) | CR (+) |
| 19 | 62 | F | IgAλ | III− del17 | RVd | VGPR | +4 | Neg | Neg | CR (+) | CR (−) |
| 20 | 61 | F | IgGκ | II | RVd | VGPR | +4 | +4 | Neg | VGPR | Relapse |
| Median, 61 Range, 51-66 | M = 4 F = 6 | I = 2 II = 4 III = 4 III = 4 | VGPR = 9 CR = 1 | 8 | 3 | 3 | VGPR = 4 CR (+) = 3 CR (−) = 2 Relapse = 1 | CR (+) = 2 CR (−) = 2 VGPR = 2 Relapse = 4 | |||
| Vaccine arm | |||||||||||
| 1 | 60 | M | κFLC | I | Rd | VGPR | Neg | Neg | +1 | CR (−) | CR (−) |
| 2 | 55 | F | IgGκ | I | Vd | VGPR | +4 | +4 | +3 | VGPR | Relapse |
| 3 | 58 | M | IgAλ | II | RVd | VGPR | Focal | Neg | +3 | CR (−) | CR (−) |
| 5 | 59 | M | IgGκ | I | RVd | VGPR | +2 | +1 | Neg | CR (−) | CR (−) |
| 7 | 55 | M | κFLC | II− del17 | RVd | VGPR | +2 | Focal | +1 | CR (+) | CR (+) |
| 9 | 64 | M | IgGλ | I | RVd | VGPR | +4 | +2 | +2 | VGPR | CR (−) |
| 11 | 59 | M | IgDλ | III− t(4;14) | RVd | VGPR | Neg | Neg | Focal | CR (+) | CR (+) |
| 13 | 55 | F | IgAκ | II | RVd | VGPR | +1 | Neg | Neg | VGPR | CR (−) |
| 15 | 61 | M | κFLC | I | KRd | CR (+) | +2 | Neg | +1 | CR (+) | CR (+) |
| 18 | 69 | M | IgGλ | II | RVd | VGPR | Focal | Focal | +3 | VGPR | VGPR |
| Median, 59 Range, 55-69 | M = 8 F = 2 | I = 5 II = 4 III = 1 | VGPR = 9 CR = 1 | 8 | 5 | 8 | VGPR = 4 CR (+) = 3 CR (−) = 3 | CR (+) = 3 CR (−) = 5 VGPR = 1 Relapse = 1 | |||
| Patient . | Age, y . | Sex . | MM subtype . | R-ISS stage . | Induction regimen . | Dz status pre-ASCT . | Antigen screening . | Dz status +3 mo . | Dz status +12 mo . | ||
|---|---|---|---|---|---|---|---|---|---|---|---|
| CT7 . | MAGE-A3 . | WT1 . | |||||||||
| Control arm | |||||||||||
| 4 | 65 | F | IgGλ | III− t(4;14) | RVd | VGPR | Neg | Neg | +1 | VGPR | Relapse |
| 6 | 66 | F | IgGκ | II | RVd | VGPR | +3 | +2 | +2 | VGPR | VGPR |
| 8 | 51 | M | IgAλ | III | CyBorD | VGPR | Focal | Neg | Neg | CR (+) | Relapse |
| 10 | 61 | F | IgAκ | I | RVd | VGPR | Neg | Neg | +1 | CR (−) | CR (+) |
| 12 | 65 | M | κFLC | II | CyBorD | VGPR | +2 | +1 | Neg | CR (+) | CR (−) |
| 14 | 52 | F | IgAλ | III− t(14;16) | KRd | CR (−) | Focal | Neg | Neg | Relapse | Relapse |
| 16 | 56 | M | IgGκ | I | KRd | VGPR | +2 | Neg | Neg | VGPR | VGPR |
| 17 | 59 | M | IgGκ | II | KRd | VGPR | Focal | Neg | Neg | CR (+) | CR (+) |
| 19 | 62 | F | IgAλ | III− del17 | RVd | VGPR | +4 | Neg | Neg | CR (+) | CR (−) |
| 20 | 61 | F | IgGκ | II | RVd | VGPR | +4 | +4 | Neg | VGPR | Relapse |
| Median, 61 Range, 51-66 | M = 4 F = 6 | I = 2 II = 4 III = 4 III = 4 | VGPR = 9 CR = 1 | 8 | 3 | 3 | VGPR = 4 CR (+) = 3 CR (−) = 2 Relapse = 1 | CR (+) = 2 CR (−) = 2 VGPR = 2 Relapse = 4 | |||
| Vaccine arm | |||||||||||
| 1 | 60 | M | κFLC | I | Rd | VGPR | Neg | Neg | +1 | CR (−) | CR (−) |
| 2 | 55 | F | IgGκ | I | Vd | VGPR | +4 | +4 | +3 | VGPR | Relapse |
| 3 | 58 | M | IgAλ | II | RVd | VGPR | Focal | Neg | +3 | CR (−) | CR (−) |
| 5 | 59 | M | IgGκ | I | RVd | VGPR | +2 | +1 | Neg | CR (−) | CR (−) |
| 7 | 55 | M | κFLC | II− del17 | RVd | VGPR | +2 | Focal | +1 | CR (+) | CR (+) |
| 9 | 64 | M | IgGλ | I | RVd | VGPR | +4 | +2 | +2 | VGPR | CR (−) |
| 11 | 59 | M | IgDλ | III− t(4;14) | RVd | VGPR | Neg | Neg | Focal | CR (+) | CR (+) |
| 13 | 55 | F | IgAκ | II | RVd | VGPR | +1 | Neg | Neg | VGPR | CR (−) |
| 15 | 61 | M | κFLC | I | KRd | CR (+) | +2 | Neg | +1 | CR (+) | CR (+) |
| 18 | 69 | M | IgGλ | II | RVd | VGPR | Focal | Focal | +3 | VGPR | VGPR |
| Median, 59 Range, 55-69 | M = 8 F = 2 | I = 5 II = 4 III = 1 | VGPR = 9 CR = 1 | 8 | 5 | 8 | VGPR = 4 CR (+) = 3 CR (−) = 3 | CR (+) = 3 CR (−) = 5 VGPR = 1 Relapse = 1 | |||
CyBorD, cyclophosphamide/bortezomib/dexamethasone; Dz, disease; F, female; KRd, carfilzomib (KYPROLIS)/lenalidomide (REVLIMID)/dexamethasone; M, male; Neg, negative; Rd, lenalidomide (REVLIMID)/dexamethasone; R-ISS, Revised International Staging System; RVd, lenalidomide (REVLIMID)/bortezomib (VELCADE)/dexamethasone; Vd, bortezomib (VELCADE)/dexamethasone; (+), MRD positive, (−), MRD negative.